FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4379284260> ?p ?o ?g. }

• W4379284260 endingPage "581" @default.
• W4379284260 startingPage "581" @default.
• W4379284260 abstract "581 Background: Several studies have established the crucial role of preexisting immune response measured by tumor-infiltrating lymphocytes (TILs) in triple-negative breast cancer (TNBC). Emerging studies showed that not only the number of TILs but also the location of TILs is as critical. There are 3 distinct immune landscapes described based on the locations of TILs, namely immune enriched (IN), immune excluded (IE), and immune desert (ID), which are associated with outcomes in TNBC treated with immune-checkpoint inhibitors. Here we evaluated characteristics associated with each immune landscape. Methods: NanoString IO360, Digital Spatial Profiling (DSP), and CosMx, a spatial multi-omics single-cell imaging platform, were used. DSP was used to quantify 39 immune-related proteins in stromal and tumor-enriched segments from 44 TNBC samples from the FinXX trial (NCT00114816) and 276 samples from the Mayo Clinic (MC) TNBC cohort (Leon-Ferre BCRT 2018). CosMx was performed in 75 samples from the MC TNBC cohort. First, tumors with TIL quantified by H&E ≤ 30% were classified as ID. The rest of the tumors were categorized according to the intratumoral CD8 protein expression by DSP, with IE having intratumoral CD8 in the lower median and IN having intratumoral CD8 in the upper median. Differential expression listed as log fold change (FC) was estimated from the linear mixed model with significance defined as two-sided p < 0.05. Results: Using DSP in the FinXX trial, intratumoral and stromal higher HLA-DR (FC 1.68, p = 0.001), B2M (FC 0.8, p = 0.005), CD4 (FC 0.74, p = 0.01), and CD40 (FC 1.56, p = 0.001) were associated with IN compared to ID. When comparing IE and IN, higher intratumoral CD11c (FC 0.97, p = 0.01) and stromal CD4 (FC 0.89, p = 0.047), CD20 (FC 0.85, p = 0.016), CD40 (FC 0.95, p = 0.045), and CD27 (FC 0.84, p = 0.024) were associated with IN. Similar findings were observed in the MC cohort. Moreover, intratumoral NY-ESO-1 expression (FC 0.55, p = 0.03) was associated with IN. Using GSEA with IO360 in the FinXX trial, PI3K-Akt signaling was associated with ID compared to IN (p = 0.01). We further evaluated the differential gene expression in a spatially resolved manner using CosMx with single-cell sequencing in the MC cohort. Expressions of MHC class I and class II in tumor cells, including HLA-A, HLA-B, HLA-C, HLA-DRA, HLA-DRB1, HLA-DPA1, and HLA-E, were associated with IN compared to ID and IE. Conclusions: Using an in-depth analysis with spatially defined context, we identified characteristics associated with distinct immune landscapes in TNBC. Our study highlights the potential future implications of intratumoral MHC expression, CD40, and PI3K-AKT as biomarkers and therapeutic targets. Clinical trial information: NCT00114816 ." @default.
• W4379284260 created "2023-06-05" @default.
• W4379284260 creator A5005801602 @default.
• W4379284260 creator A5006782806 @default.
• W4379284260 creator A5008665323 @default.
• W4379284260 creator A5015019391 @default.
• W4379284260 creator A5016908886 @default.
• W4379284260 creator A5022850305 @default.
• W4379284260 creator A5026692399 @default.
• W4379284260 creator A5031005364 @default.
• W4379284260 creator A5033544737 @default.
• W4379284260 creator A5052187738 @default.
• W4379284260 creator A5065306642 @default.
• W4379284260 creator A5069569795 @default.
• W4379284260 creator A5082913203 @default.
• W4379284260 creator A5083904553 @default.
• W4379284260 creator A5085014608 @default.
• W4379284260 creator A5087508472 @default.
• W4379284260 creator A5088803460 @default.
• W4379284260 creator A5090618504 @default.
• W4379284260 date "2023-06-01" @default.
• W4379284260 modified "2023-09-25" @default.
• W4379284260 title "Characteristics associated with spatially resolved immune landscapes in triple-negative breast cancer in the FinXX trial and Mayo Clinic cohort." @default.
• W4379284260 doi "https://doi.org/10.1200/jco.2023.41.16_suppl.581" @default.
• W4379284260 hasPublicationYear "2023" @default.
• W4379284260 type Work @default.
• W4379284260 citedByCount "0" @default.
• W4379284260 crossrefType "journal-article" @default.
• W4379284260 hasAuthorship W4379284260A5005801602 @default.
• W4379284260 hasAuthorship W4379284260A5006782806 @default.
• W4379284260 hasAuthorship W4379284260A5008665323 @default.
• W4379284260 hasAuthorship W4379284260A5015019391 @default.
• W4379284260 hasAuthorship W4379284260A5016908886 @default.
• W4379284260 hasAuthorship W4379284260A5022850305 @default.
• W4379284260 hasAuthorship W4379284260A5026692399 @default.
• W4379284260 hasAuthorship W4379284260A5031005364 @default.
• W4379284260 hasAuthorship W4379284260A5033544737 @default.
• W4379284260 hasAuthorship W4379284260A5052187738 @default.
• W4379284260 hasAuthorship W4379284260A5065306642 @default.
• W4379284260 hasAuthorship W4379284260A5069569795 @default.
• W4379284260 hasAuthorship W4379284260A5082913203 @default.
• W4379284260 hasAuthorship W4379284260A5083904553 @default.
• W4379284260 hasAuthorship W4379284260A5085014608 @default.
• W4379284260 hasAuthorship W4379284260A5087508472 @default.
• W4379284260 hasAuthorship W4379284260A5088803460 @default.
• W4379284260 hasAuthorship W4379284260A5090618504 @default.
• W4379284260 hasConcept C121608353 @default.
• W4379284260 hasConcept C126322002 @default.
• W4379284260 hasConcept C143998085 @default.
• W4379284260 hasConcept C167672396 @default.
• W4379284260 hasConcept C16930146 @default.
• W4379284260 hasConcept C203014093 @default.
• W4379284260 hasConcept C2778326572 @default.
• W4379284260 hasConcept C2780110267 @default.
• W4379284260 hasConcept C502942594 @default.
• W4379284260 hasConcept C530470458 @default.
• W4379284260 hasConcept C71924100 @default.
• W4379284260 hasConcept C72563966 @default.
• W4379284260 hasConcept C8891405 @default.
• W4379284260 hasConceptScore W4379284260C121608353 @default.
• W4379284260 hasConceptScore W4379284260C126322002 @default.
• W4379284260 hasConceptScore W4379284260C143998085 @default.
• W4379284260 hasConceptScore W4379284260C167672396 @default.
• W4379284260 hasConceptScore W4379284260C16930146 @default.
• W4379284260 hasConceptScore W4379284260C203014093 @default.
• W4379284260 hasConceptScore W4379284260C2778326572 @default.
• W4379284260 hasConceptScore W4379284260C2780110267 @default.
• W4379284260 hasConceptScore W4379284260C502942594 @default.
• W4379284260 hasConceptScore W4379284260C530470458 @default.
• W4379284260 hasConceptScore W4379284260C71924100 @default.
• W4379284260 hasConceptScore W4379284260C72563966 @default.
• W4379284260 hasConceptScore W4379284260C8891405 @default.
• W4379284260 hasFunder F4320306260 @default.
• W4379284260 hasIssue "16_suppl" @default.
• W4379284260 hasLocation W43792842601 @default.
• W4379284260 hasOpenAccess W4379284260 @default.
• W4379284260 hasPrimaryLocation W43792842601 @default.
• W4379284260 hasRelatedWork W1966181922 @default.
• W4379284260 hasRelatedWork W1999292713 @default.
• W4379284260 hasRelatedWork W2101673433 @default.
• W4379284260 hasRelatedWork W2366029130 @default.
• W4379284260 hasRelatedWork W2376078656 @default.
• W4379284260 hasRelatedWork W2554176272 @default.
• W4379284260 hasRelatedWork W3005028195 @default.
• W4379284260 hasRelatedWork W3099981825 @default.
• W4379284260 hasRelatedWork W80971072 @default.
• W4379284260 hasRelatedWork W4287555501 @default.
• W4379284260 hasVolume "41" @default.
• W4379284260 isParatext "false" @default.
• W4379284260 isRetracted "false" @default.
• W4379284260 workType "article" @default.